- Home
- UAMY vs CRVS Comparison
UAMY vs CRVS Comparison
Compare UAMY & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAMY
- CRVS
- Stock Information
- Founded
- UAMY 1968
- CRVS 2014
- Country
- UAMY United States
- CRVS United States
- Employees
- UAMY N/A
- CRVS N/A
- Industry
- UAMY Metal Fabrications
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- UAMY Industrials
- CRVS Health Care
- Exchange
- UAMY Nasdaq
- CRVS Nasdaq
- Market Cap
- UAMY 251.9M
- CRVS 206.5M
- IPO Year
- UAMY N/A
- CRVS 2016
- Fundamental
- Price
- UAMY $2.46
- CRVS $3.78
- Analyst Decision
- UAMY Strong Buy
- CRVS Strong Buy
- Analyst Count
- UAMY 4
- CRVS 4
- Target Price
- UAMY $3.38
- CRVS $15.00
- AVG Volume (30 Days)
- UAMY 3.4M
- CRVS 1.4M
- Earning Date
- UAMY 05-08-2025
- CRVS 05-08-2025
- Dividend Yield
- UAMY N/A
- CRVS N/A
- EPS Growth
- UAMY N/A
- CRVS N/A
- EPS
- UAMY N/A
- CRVS N/A
- Revenue
- UAMY $18,865,900.00
- CRVS N/A
- Revenue This Year
- UAMY $270.45
- CRVS N/A
- Revenue Next Year
- UAMY $104.06
- CRVS N/A
- P/E Ratio
- UAMY N/A
- CRVS N/A
- Revenue Growth
- UAMY 97.46
- CRVS N/A
- 52 Week Low
- UAMY $0.27
- CRVS $1.75
- 52 Week High
- UAMY $3.86
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- UAMY 41.82
- CRVS 54.46
- Support Level
- UAMY $2.30
- CRVS $3.38
- Resistance Level
- UAMY $2.62
- CRVS $3.94
- Average True Range (ATR)
- UAMY 0.23
- CRVS 0.25
- MACD
- UAMY -0.06
- CRVS 0.01
- Stochastic Oscillator
- UAMY 16.67
- CRVS 34.78
About UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has four operating segments: United States Antimony, Mexican antimony, zeolite, and Precious metals. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).